Key Drivers
- Durable Margins
- Weak Cash Conversion
- Elevated Leverage
AIAI Summary
GEHC's investment case hinges on converting its $23.9B backlog and premium imaging/AI offerings into revenue growth above its 3%–4% outlook and materially stronger free-cash-flow conversion; the current valuation is reasonable, but not low enough to absorb another execution miss. Investors should wait for evidence of improving backlog conversion, margins, and cash generation—particularly amid PCS weakness and reduced liquidity—before treating the oversold share price as a durable buying opportunity.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Durable Margins
- •Weak Cash Conversion
- •Elevated Leverage
GE HealthCare offers durable margins and moderate valuation, but declining liquidity, weak recent cash conversion, and high leverage/intangibles warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Persistent selling
- •Critical support
- •Oversold rebound
GEHC remains in a last-month downtrend, with $63.50–$64.00 support critical and a rebound needing a sustained move above $65.15–$66.80.
Accelerated drop from $68.86 to $65.17 between 2026-09-04 and 2026-09-09
Sentiment & News
Key News Insights:
- •Record Backlog
- •Ultrasound Expansion
- •Legal Overhang
GE HealthCare's strong orders, backlog, product innovation, and institutional buying support growth visibility, but margin, debt, and securities-investigation risks remain key overhangs.
Growth momentum may support GEHC's valuation, though legal and margin risks could constrain near-term sentiment
Similar Companies in Healthcare
Other companies in the same sector with AI ratings